

Attorney Docket No.: P33114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Branch et al.

March 15, 2005

Int'l. Appln. No.: PCT/EP03/010412

Group Art Unit: Not Yet Assigned

Int'l. Filing Date: 17 September 2003

Examiner: Not Yet Assigned

For: N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR
ANTAGONISTS

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

Commissioner for Patents
P.O. Box 1450
Alexandria, Va 22313-1450

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and **(e)**, respectively, are the same.
- (X) I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)** does not include new matter.
- (X) I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**, included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.

Serial No.: PCT/EP03/010412
Group Art Unit No.: Not Yet Assigned

10/527833
DT [redacted] PCT/PTO 15 MAR 2005

- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\kls\cases\p33114\Sequence Listing Transmittal.doc